IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4186
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$43M
Frédéric Guerard
CalciMedica, Inc. focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials. GB-401, an implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$CALC CalciMedica, Inc. | 34 | 31 | 36 | 42 | - | - | -526.4% | -163.8% | - | - | - | - | 0.0% | - | $43M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
CalciMedica, Inc. (CALC) receives a "Avoid" rating with a composite score of 34.3/100. It ranks #4186 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Equity capital efficiency
Asset base utilization
Direct cash return
Frédéric Guerard
Chief Executive Officer
Labor Force
30
31
25
32
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for CALC
In-line with peers — no strong momentum signal
Fair valuation relative to peers
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
No analyst ratings for CALC.
View All RatingsInsufficient data for Financial Analysis
ROE proxy -526.4% (sector -2.5%)
GM N/A vs sector 43%, OM N/A vs sector 1%
Capital turnover N/A
Rev growth N/A, 6yr history
Interest coverage -17.2x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags CalciMedica, Inc. with an Avoid rating, assigning a composite score of 34.3/100 and 1 out of 5 stars. Ranked #4186 of 7,333 stocks, CALC falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
CALC's quality score of 31/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -526.4% (sector avg: -2.5%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 36/100, CALC appears somewhat expensive relative to its fundamentals. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
CalciMedica, Inc.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -163.8% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
CALC is currently showing below-average momentum at 42/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth data is not currently available, while a beta of 0.22 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
CALC's stability score of 32/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 0.22. Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
The short interest score of 49/100 for CALC suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include micro-cap liquidity risk. With a $43M market cap (micro-cap), CalciMedica, Inc. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
CalciMedica, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4186 of 7,333 overall (43rd percentile). Key comparisons include ROE of -526.4% trailing the -2.5% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While CALC currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Investment (25) would have the largest impact on the composite score.
ROE 21124% ABOVE SECTOR MEDIAN (FAVORABLE)
Div. Yield NaN% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate CalciMedica, Inc. (CALC) as Avoid with a composite score of 34.3/100 at a current price of $0.59. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in momentum (42th percentile) and value (36th percentile), which together account for the majority of the composite score. Offsetting weakness in investment (25th percentile) and quality (31th percentile) tempers our overall conviction. We assign a No Moat rating (17/100), Low uncertainty, and Poor capital allocation.
Key items to watch: quarterly earnings execution and sector-level competitive dynamics. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
CalciMedica, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 34.3/100 places it at rank #4186 in our full 7,333-stock universe. At $43M in market capitalization, CalciMedica, Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Momentum indicators (42th percentile) are neutral regarding the near-term price trend. Revenue growth data is unavailable, limiting our ability to confirm whether momentum is fundamentally supported.
Margin data is not available for CalciMedica, Inc., which limits our assessment of the company's cost structure and operating efficiency. We rely on factor-based signals to infer business quality in the absence of detailed margin data.
At a current price of $0.59, CalciMedica, Inc. is trading at a premium to fundamental value. Our value factor score of 36/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
Valuation multiples are not available for this company, which limits our ability to assess relative pricing. We rely more heavily on factor-based valuation signals in such cases.
The stock may offer contrarian value if near-term headwinds prove transitory — the current weakness in factor scores may reverse if business fundamentals stabilize.
The Avoid rating (composite 34.3/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Below-average quality (31th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
We assign a Low uncertainty rating to CalciMedica, Inc.. The company exhibits strong financial stability with a beta of 0.22, and a stability factor in the 32th percentile. The predictable nature of the business model and solid financial position reduce the range of potential outcomes, giving us confidence in our fair value estimate.
Specific risk factors that inform our assessment include: below-average price stability (32th percentile); weak quality scores (31th percentile); low beta of 0.22 — while defensive, this may indicate limited upside participation in bull markets. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 32th percentile and quality factor at the 31th percentile provide a quantitative summary of the overall risk landscape.
We identify limited risk mitigants at this time, which contributes to our low uncertainty assessment. Investors should monitor for improvement in balance sheet metrics, margin stability, and business predictability that could warrant a downgrade in our risk assessment over time.
We rate CalciMedica, Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-526.4%), weak asset returns (ROA -163.8%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — CalciMedica, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, CalciMedica, Inc. receives a Avoid rating with a composite score of 34.3/100 (rank #4186 of 7,333). Our quantitative framework assigns a No Moat (17/100, trend: stable), Low uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 33/100.
Our analysis does not support a constructive view on CalciMedica, Inc. at this time. The combination of limited competitive advantages, low uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign CalciMedica, Inc. a meaningful economic moat, scoring 17/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 10/20.
The strongest moat sources are margin superiority (10/20) and growth durability (4.9/20). GM N/A vs sector 43%, OM N/A vs sector 1%. Rev growth N/A, 6yr history. These pillars form the core of CalciMedica, Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and financial resilience (0/20). Capital turnover N/A. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect CalciMedica, Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers are not clearly identifiable from current fundamentals. This may reflect a company in transition, a cyclical downturn, or structural challenges in the business model. We assign a quality factor of 31/100 which further underscores our concern regarding earnings sustainability.
Return metrics include ROE of -526.4% and ROA of -163.8%. Relative to the Manufacturing sector, sector comparison data is limited, and ROE of -526.4% compares to a sector median of -2.5%.
Balance sheet data is limited, restricting our assessment of financial resilience. Investors should seek additional disclosure on leverage and liquidity before forming a complete view of financial health.
Above 50MA
37.18%
Net New Highs
+51081
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138. FaZe Holdings Inc. (NASDAQ: FAZE) gained 46.9% to $0.2247 after falling over 4% on Friday. Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares climbed 23.5% to $0.1472 after gaining 16% on Friday. The company recently announced the sale of its assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) on Sept. 12. Biophytis S.A. (NASDAQ: BPTS) shares gained 22.3% to $1.1250 after the company and Skyepharma announced the signature of a partnership agreement for the production of regulatory batches of Sarconeos (BIO101) for severe forms of Covid-19. Cano Health, Inc. (NYSE: CANO) rose 20.5% to $0.2727. Sharps Technology, Inc. (NASDAQ: STSS) surged 18.2% to $0.6703. CalciMedica, Inc. (NASDAQ: CALC) climbed 16.3% to $3.0699. TradeUP Acquisition Corp. (NASDAQ: UPTD) gained 14% to $14.50 So-Young International Inc. (NASDAQ: SY) gained 13.5% to $1.2263. Shattuck Labs, Inc. (NASDAQ: STTK) rose 13.3% to $1.71. Pasithea Therapeutics Corp. (NASDAQ: KTTA) gained 13.1% to $0.4998. Enthusiast Gaming Holdings Inc. (NASDAQ: EGLX) gained 12.7% to $0.3367. InnSuites Hospitality Trust (NYSE: IHT) surged 12.5% to $1.4399. Canopy Growth Corporation (NASDAQ: CGC) rose 12.5% to $0.9422. ESS Tech, Inc. (NYSE: GWH) shares climbed 10.1% to $1.53. Honeywell International Inc (NASDAQ: HON) entered into a strategic collaboration with ESS Tech to advance technology development and market adoption of iron flow battery (IFB) energy storage systems. Solo Brands, Inc. (NYSE: DTC) gained 10% to $4.9605. ...
Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health. Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) surged 76.3% to $3.2450 after the company announced initial dose escalation data demonstrated anti-tumor activity of BDTX-1535 in non-small cell lung cancer patients across multiple EGFR mutation families. Centogene N.V. (NASDAQ: CNTG) rose 49% to $1.1675 after the company and Lifera formed a Saudi Arabian joint venture. Under the terms of the collaboration, the company will receive a $30 million mandatory convertible loan from Lifera. CalciMedica, Inc. (NASDAQ: CALC) climbed 37% to $4.43. Cara Therapeutics, Inc. (NASDAQ: CARA) gained 22.1% to $3.9547. Cara Therapeutics was granted U.S. Patent #11684674: Oral formulations of kappa opioid receptor agonists. AC Immune SA (NASDAQ: ACIU) rose 19.2% to $2.36 after the company received FDA fast track designation for anti-amyloid-beta active immunotherapy, ACI-24.060 for Alzheimer's disease. American Equity Investment Life Holding Company (NYSE: AEL) shares gained 17.6% to $53.02 after the company announced it has received a $55 per share acquisition proposal from Brookfield Reinsurance. American Rebel Holdings, Inc. (NASDAQ: AREB) jumped 16.6% to $5.47. Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) rose 16.6% to $0.0729. IronNet, Inc. (NYSE: IRNT) gained 14.8% to $0.2067 after dropping 13% on Monday. Astrotech Corporation (NASDAQ: ASTC) gained 13.5% to $12.95. Astrotech 13D filing showed BML Investment Partners, L.P. increased stake in the company to 13%. Aterian, Inc. (NASDAQ: ATER) rose 13% to $0.4099. Enovix Corporation (NASDAQ: ENVX) gained 12.1% to $14.71 after the company announced it received a purchase order to produce battery cells for the U.S. Army. WeWork Inc. (NYSE: WE) rose 11.1% to $0.2601. Moolec Science SA (NASDAQ: MLEC) gained 10.7% to $4.1817. Edgewise Therapeutics, Inc. (NASDAQ: EWTX) rose 9.9% to $7.54 as the company released 12-month topline results from the ARCH study, an open-label, single-center study assessing EDG-5506 in adults with Becker Muscular Dystrophy (BMD). NextPlay Technologies, Inc. (NASDAQ: NXTP) surged ...
Upgrades Tudor Pickering upgraded the previous rating for EQT Corp (NYSE:EQT) from Hold to Buy. EQT earned $1.70 in the first quarter, compared to $0.81 in the year-ago quarter. At the moment, the stock has a 52-week-high of $51.95 and a 52-week-low of $28.11. EQT closed at $39.64 at the end of the last trading period. According to Wells Fargo, the prior rating for Ball Corp (NYSE:BALL) was changed from Underweight to Equal-Weight. Ball earned $0.69 in the first quarter, compared to $1.37 in the year-ago quarter. At the moment, the stock has a 52-week-high of $74.34 and a 52-week-low of $46.00. Ball closed at $58.43 at the end of the last trading period. Morgan Stanley upgraded the previous rating for Avis Budget Group Inc (NASDAQ:CAR) from Equal-Weight to Overweight. Avis Budget Gr earned $7.72 in the first quarter, compared to $9.99 in the year-ago quarter. The current stock performance of Avis Budget Gr shows a 52-week-high of $251.26 and a 52-week-low of $131.85. Moreover, at the end of the last trading period, the closing price was at $204.29. According to Morgan Stanley, the prior rating for US Foods Holding Corp (NYSE:USFD) was changed from Equal-Weight to Overweight. In the first quarter, US Foods Hldg showed an EPS of $0.50, compared to $0.36 from the year-ago quarter. The stock has a 52-week-high of $42.36 and a 52-week-low of $25.55. At the end of the last trading period, US Foods Hldg closed at $41.65. According to Morgan Stanley, the prior rating for Baidu Inc (NASDAQ:BIDU) was changed from Equal-Weight to Overweight. In the first quarter, Baidu showed an EPS of $2.34, compared to $1.77 from the year-ago quarter. The current stock performance of Baidu shows a 52-week-high of $160.88 and a 52-week-low of $73.59. Moreover, at the end of the last trading period, the closing price was at $145.11. Credit Suisse upgraded the previous rating for Studio City International Holdings Ltd (NYSE:MSC) from Neutral to Outperform. In the first quarter, Studio City Intl Hldgs showed an EPS of $0.17, compared to $0.54 from the year-ago quarter. According to Credit Suisse, the prior rating for Melco Resorts and Entertainment Ltd (NASDAQ:MLCO) was changed from Neutral to Outperform. Melco Resorts and Enter earned $0.14 in the first quarter, compared to $0.37 in the year-ago quarter. At the moment, the stock has a 52-week-high of $14.46 and a 52-week-low of $4.70. Melco Resorts and Enter closed at $12.52 at the end of the last trading period. JMP Securities upgraded the previous rating for EPR Properties (NYSE:EPR) from Market Perform to Market Outperform. For the first quarter, EPR Props had an EPS of $1.26, compared to year-ago quarter EPS of $1.10. The stock has a 52-week-high of $55.90 and a 52-week-low of $33.92. At the end of the last trading period, EPR Props closed at $45.80. For Philip Morris International Inc (NYSE:PM), Citigroup upgraded the previous rating of Neutral to Buy. Philip Morris Intl earned $1.38 in the first quarter, compared to $1.58 in the year-ago quarter. The current stock performance of Philip Morris Intl shows a 52-week-high of $105.62 and a 52-week-low of $82.85. Moreover, at the end of the last trading period, the closing price was at $94.89. Keybanc upgraded the previous rating for Universal Stainless & Alloy Products Inc (NASDAQ:USAP) from Sector Weight to Overweight. In the first quarter, Universal Stainless showed an EPS of $0.06, compared to $0.18 from the year-ago quarter. The current stock performance of Universal Stainless shows a 52-week-high of $12.34 and a 52-week-low of $6.56. Moreover, at the end of the last trading period, the closing price was at $12.00. See all analyst ratings upgrades. Downgrades For Nike Inc (NYSE:NKE), OTR Global downgraded the previous rating of Positive to Mixed. Nike earned $0.79 in the third quarter, compared to $0.87 in the year-ago quarter. At the moment, the stock has a 52-week-high of $131.31 and a 52-week-low of $82.24. Nike closed at $113.59 at the end of the last trading period. For Portland General Electric Co (NYSE:POR), Guggenheim downgraded the previous rating of Buy to Neutral. Portland Gen Electric earned $0.80 in the first quarter, compared to $0.67 in the year-ago quarter. The stock has a 52-week-high of $56.26 and a 52-week-low of $41.68. At the end of the last trading period, Portland Gen Electric closed at $48.67. Wedbush downgraded the previous rating for Surface Oncology Inc (NASDAQ:SURF) from Outperform to Neutral. Surface Oncology earned $0.33 in the first quarter, compared to $0.13 in the year-ago quarter. At the moment, the stock has a 52-week-high of $2.14 and a 52-week-low of $0.56. Surface Oncology closed at $0.79 at the end of the last trading period. Baird downgraded the previous rating for Surface Oncology Inc (NASDAQ:SURF) from Outperform to Neutral. Surface Oncology earned $0.33 in the first quarter, compared to $0.13 in the year-ago quarter. The current stock performance of Surface Oncology shows a 52-week-high of $2.14 and a 52-week-low of $0.56. Moreover, at the end of the last trading period, the closing price was at $0.79. Morgan Stanley downgraded the previous rating for Performance Food Group Co (NYSE:PFGC) from Overweight to Equal-Weight. In the third quarter, Performance Food Gr showed an EPS of $0.83, compared to $0.51 from the year-ago quarter. The stock has a 52-week-high of $63.22 and a 52-week-low of $38.81. At the end of the last trading period, Performance Food Gr closed at $56.31. For Surface Oncology Inc (NASDAQ:SURF), HC Wainwright & Co. downgraded the previous rating of Buy to Neutral. Surface Oncology earned $0.33 in the first quarter, compared to $0.13 in the year-ago quarter. The current stock performance of Surface Oncology shows a 52-week-high of $2.14 and a 52-week-low of $0.56. Moreover, at the end of the last trading period, the closing price was at $0.79. Raymond James downgraded the previous rating for Palantir Technologies Inc (NYSE:PLTR) from Strong Buy to Outperform. In the first quarter, Palantir Technologies showed an EPS of $0.05, compared to $0.02 from the year-ago quarter. The current stock performance of Palantir Technologies shows a 52-week-high of $17.16 and a 52-week-low of $5.84. Moreover, at the end ...Full story available on Benzinga.com